Enliven Therapeutics (NASDAQ:ELVN) Stock: Insider J. Scott Garland Sells 13,000 Shares

Key Points

• Director J. Scott Garland sold 13,000 Enliven shares at an average price of $46.67, generating $606,710 and reducing his direct ownership by 50%.
• Enliven shares fell 3.2% to $45.47, while the company reported quarterly EPS of negative $0.49, missing analysts’ estimate of negative $0.39.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and a $74.44 target price; institutional investors own approximately 95.08% of the stock.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director J. Scott Garland sold 13,000 shares of the firm's stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the transaction, the director directly owned 13,000 shares of the company's stock, valued at $606,710. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Enliven Therapeutics Stock Down 3.2%

Shares of NASDAQ:ELVN traded down $1.50 during midday trading on Monday, reaching $45.47. 821,495 shares of the company traded hands, compared to its average volume of 1,258,190. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $62.32. The firm has a market capitalization of $3.33 billion, a price-to-earnings ratio of -27.23 and a beta of 0.24. The firm's fifty day moving average price is $55.23 and its two-hundred day moving average price is $47.39.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Analysts forecast that Enliven Therapeutics, Inc. will post -1.75 earnings per share for the current year.

Analyst Ratings Changes

ELVN has been the subject of several recent analyst reports. HC Wainwright boosted their price objective on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a research note on Thursday, July 9th. William Blair started coverage on shares of Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an "outperform" rating on the stock. JonesTrading upped their price target on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Barclays began coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They issued an "overweight" rating and a $78.00 price objective on the stock. Finally, Mizuho lifted their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the company an "outperform" rating in a research note on Tuesday, August 18th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $74.44.

Institutional Investors Weigh In On Enliven Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC lifted its position in Enliven Therapeutics by 574.1% during the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company's stock valued at $69,058,000 after purchasing an additional 1,158,883 shares during the last quarter. Tidal Investments LLC raised its position in shares of Enliven Therapeutics by 27.7% during the 2nd quarter. Tidal Investments LLC now owns 60,694 shares of the company's stock valued at $3,080,000 after buying an additional 13,179 shares in the last quarter. WINTON GROUP Ltd bought a new stake in shares of Enliven Therapeutics during the 2nd quarter worth $228,000. Engineers Gate Manager LP purchased a new position in Enliven Therapeutics in the second quarter worth $1,479,000. Finally, Squarepoint Ops LLC bought a new position in Enliven Therapeutics in the second quarter valued at $259,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc NASDAQ: ELVN is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability.

Enliven's pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.